Target intelligence / Profile preview

Mitochondrial Rho GTPase 1 (MIRO1)

Target
MIRO1
Molecular classification
Small GTPase, Mitochondrial Rho GTPase, Outer mitochondrial membrane protein, Enzyme (nucleoside-triphosphatase)
01

Overview

Mitochondrial Rho GTPase 1 (MIRO1) is an atypical Rho GTPase anchored in the outer mitochondrial membrane and encoded by the RHOT1 gene. It contains two GTPase domains (N-terminal and C-terminal), EF-hand calcium-binding motifs, and a transmembrane region. MIRO1 plays a crucial role in mitochondrial trafficking along microtubules, mitochondrial dynamics, and cellular calcium homeostasis. It is essential for neuronal function, particularly in facilitating mitochondrial movement to energy-demanding locations and regulating mitophagy through interactions with proteins such as PINK1 and Parkin. MIRO1 dysfunction and mutations are implicated in neurodegenerative diseases (notably Parkinson’s disease), as well as various cancers, due to its involvement in mitochondrial quality control, apoptosis, and cellular metabolism[1][2][3][5].

Other names
Ras homolog family member T1 (RHOT1)ARHT1hMiro-1Miro-1FLJ11040MIRO1Rac-GTP-binding protein-like proteinMIRO-1rac-GTP binding protein-like protein
02

Mechanism of action

Targeting of MIRO1 for proteasomal degradation (ubiquitination by Parkin after phosphorylation by PINK1)[1][5]; Modulation of mitochondrial arrest to facilitate mitophagy[1][5]

03

Biological functions

Regulation of mitochondrial transport along microtubulesMitochondrial homeostasisCalcium-dependent mitochondrial positioningRegulation of mitochondrial morphology/fissionMitophagyApoptosis
04

Disease associations

Neurodegenerative disease (notably Parkinson’s disease)[1][5]Cancer (including pancreatic and breast cancer)[1][3]Myopathy with extrapyramidal signs[3]
05

Safety considerations

Potential for neurotoxicity via disruption of mitochondrial transport or mitophagy (loss or gain of function)[5]Impaired cellular energy homeostasis or calcium buffering in neuronsRisk of off-target mitochondrial or peroxisome dysfunction
06

Interacting drugs

None currently established as direct RHOT1/MIRO1 modulators in clinical use or trials as of September 2025. Target is under investigation; experimental compounds and research tools (e.g., Parkin/PINK1 axis modulators) may affect MIRO1 indirectly[1][5].
07

Biomarkers

Mutations in RHOT1/MIRO1 gene for Parkinson’s disease patient stratificationaltered MIRO1 protein levels or degradation dynamics may potentially act as biomarkers pending further research[5]

Beyond the preview

Go deeper on Mitochondrial Rho GTPase 1 (MIRO1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitochondrial Rho GTPase 1 (MIRO1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call